--
--(--)
--
--(--)
Expected P&L on Expiry
Key Stats
0.00DAY`S RANGE0.00
0.00
0.00
--
--
--
--
--
--
--
Pricing Model
--
--
--
--
--
--
About ABVX20260515P160
Biological Technology
Abivax Sa was incorporated on December 4, 2013 under the laws of France. The company is a clinical-stage biotechnology company focused on developing therapies that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is currently evaluating the lead drug candidate, Oberfazmod, in a Phase 3 clinical trial for the treatment of moderate-to-severe active ulcerative colitis in adults.
